Antibiotic Collaboration and Licensing Deals 2016-2025

Antibiotic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse antibiotic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in antibiotic dealmaking
2.1. Introduction
2.2. Antibiotic deals over the years
2.3. Most active antibiotic dealmakers
2.4. Antibiotic deals by deal type
2.5. Antibiotic deals by therapy area
2.6. Antibiotic deals by industry sector
2.7. Deal terms for antibiotic deals
2.7.1 Antibiotic deals headline values
2.7.2 Antibiotic deal upfront payments
2.7.3 Antibiotic deal milestone payments
2.7.4 Antibiotic royalty rates

Chapter 3 – Leading antibiotic deals
3.1. Introduction
3.2. Top antibiotic deals by value

Chapter 4 – Most active antibiotic dealmakers
4.1. Introduction
4.2. Most active antibiotic dealmakers
4.3. Most active antibiotic deals company profiles

Chapter 5 – Antibiotic contracts dealmaking directory
5.1. Introduction
5.2. Antibiotic contracts dealmaking directory

Chapter 6 – Antibiotic dealmaking by technology type

Deal directory

Deal directory – Antibiotic deals by company A-Z
Deal directory – Antibiotic deals by deal type
Deal directory – Antibiotic deals by therapy area

Deal type definitions

About Biopharma Research Ltd 
Current Partnering
Current Agreements
Recent report titles from Current Partnering

 
Table of figures

Figure 1: Antibiotic deals since 2016
Figure 2: Active antibiotic dealmaking activity – 2016 - 2025
Figure 3: Antibiotic deals by deal type since 2016
Figure 4: Antibiotic deals by therapy area since 2016
Figure 5: Antibiotic deals by industry sector since 2016
Figure 6: Antibiotic deals with a headline value
Figure 7: Antibiotic deals with an upfront value
Figure 8: Antibiotic deals with a milestone value
Figure 9: Antibiotic deals with a royalty rate value
Figure 10: Top antibiotic deals by value since 2016
Figure 11: Most active antibiotic dealmakers 2016 - 2025
Figure 12: Antibiotic deals by technology type since 2016

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3B Pharmaceuticals, Achaogen, Acino Pharma, Acurx Pharmaceuticals, Advanz Pharma, Allecra Therapeutics, Allergan, Amerigen Pharmaceuticals, Amicogen, AMR, Amyris, Antibiotic Research UK, Appili Therapeutics, Arrevus, Artizan Biosciences, AstraZeneca, Australian Research Council, Avails Medical, Basilea Pharmaceutica, Biomedical Advanced Research and Development Authority, Biophore Pharmaceuticals, BioVersys, Blacksmith Medicines, Boston Pharmaceuticals, Boston University, Boulos and Cooper Pharmaceuticals, Brii Biosciences, Bugworks, California Institute for Biomedical Research, CARB-X, Centre for Drug Research and Development (CDRD), Cepheid, Checkpoint Therapeutics, Chelexa Biosciences, Cidara Therapeutics, Citius Pharmaceuticals, Cleveland Clinic, Clinton Health Access Initiative, Correvio Pharma, Cosmo Pharmaceuticals, Crestone Pharma, CSPC Pharmaceutical Group, Cumberland Pharmaceuticals, Cystic Fibrosis Foundation, Dana-Farber Cancer Institute, Debiopharm, Decibel Therapeutics, Defense Threat Reduction Agency, Deinove, Department of Defense, Department of Health and Human Services, Dermin, Dr. Reddy's Laboratories, DSM Sinochem Pharmaceuticals, Entasis Therapeutics, Enterome Bioscience, Eurofarma, European Investment Bank, Everest Medicines, Evotec, Federal Ministry of Education and Research (BMBF), Flightpath Biosciences, Florida International University, Forge Therapeutics, Forsyth Institute, Foundation for Innovative New Diagnostics, Geom Therapeutics, Global Antibiotic Research and Development Partnership, GPCR Therapeutics, GSK, Hackensack Meridian Health, Harvard Medical School, Hasten Biopharmaceutic, Helmholtz Centre for Infection Research, Helperby Therapeutics, Hikma Pharmaceuticals, Hoffmann La Roche, Hoth Therapeutics, Hvidovre Hospital, Ichor Biologics, InfectoPharm, Infex Therapeutics, InfoRLife, Ingenza, Innosuisse, Innovate UK, Innoviva, Innoviva Specialty Therapeutics, Insmed Inc, Italfarmaco, Johns Hopkins University, Journey Medical, Kinnear Pharmaceuticals, Knauer Scientific Instruments, LegoChem Biosciences, LEO Pharma, Leukocare, LifeArc, Liverpool School of Tropical Medicine, Luminarie, Lysando, Macrolide Pharma, Magle Chemoswed, Matinas Biopharma, MD Anderson Cancer Center, Medicines Patent Pool Foundation, Meitheal Pharmaceuticals, Melinta Therapeutics, Menarini, Merck and Co, Microbiotix, MicuRx Pharmaceuticals, Moleculin Biotech, Monash University, Nabriva Therapeutics, Nanjing King-friend Biochemical Pharmaceutical, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, National Institutes of Health, Navamedic, Next Gen Diagnostics, Nosopharm, Novartis, Opal Therapeutics, OpGen, Oragenics, Oricula Therpeutics, Oxford Drug Design, Paratek Pharmaceuticals, Pfizer, Phico Therapeutics, Pieces Technologies, Polyphor, Prokaryotics, Q-linea AB, Qpex Biopharma, QureTech Bio, Recce Pharmaceuticals, Recida Therapeutics, RedHill Biopharma, RMX Biopharma, Roche, Sandoz, Saptalis Pharmaceuticals, SeLux Diagnostics, Shanghai Haini Pharmaceutical, Shenzhen China Resources Gosun Pharmaceutical, Shionogi, Sinovant Sciences, SpeeDx, Spero Therapeutics, Strides Pharma Science, Summit Therapeutics, Suzhou NeuPharma, Swixx Biopharma, Tabuk Pharmaceutical, Taiba, TaiGen Biotechnology, TB Alliance, Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, The Medicines Company, Theravance Biopharma, Thermo Fisher Scientific, TLC BioSciences, Trellis Bioscience, University of Bergen, University of California Los Angeles, University of Florida, University of Liverpool, University of Melbourne, University of New South Wales, University of Queensland, University of Technology Sydney, University of Zurich, US Army Medical Research Institute of Infectious Diseases, UTILITY Therapeutics, UT Southwestern Medical Center, VenatoRx, Verity Pharmaceuticals, Vertex Pharmaceuticals, Vinnova, Warp Drive Bio, Wellcome Trust, Wuxi Apptec Laboratory Services, X-Biotix Therapeutics, X-chem, Xellia Pharmaceuticals, ZAI Laboratory, Zoetis, Zydus Cadila

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements

• SEC filings and equivalent regulatory disclosures

• Company and investor presentations

• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development

• Research and collaborative R&D

• Manufacturing, supply, and distribution

• Commercialisation and co-promotion

• Equity investments, joint ventures, and asset transactions

• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties

• Rights allocation — development, manufacturing, and commercialization responsibilities

• Deal structure — exclusivity, territorial scope, and agreement type

• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type

• Stage of development

• Asset type and deal components

• Geographic scope and exclusivity

• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered

• How responsibilities are operationalised between parties

• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making, including:

• Benchmarking comparable transactions

• Supporting valuation and deal structuring

• Preparing for negotiations

• Evaluating potential partners

• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies and emerging biotechs as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.